Vincerx Pharma
VINC
Market cap $22.5M

0.7300 USD

+0.0147

2.06%

At close Oct 4, 4:00 PM EDT

After hours

0.7200

-0.0100

1.37%

1 day

2.06%

5 days

1.54%

1 month

2.24%

3 months

4.08%

6 months

-84.73%

Year to date

-38.14%

1 year

-27.00%

5 years

-96.27%

About: Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.

Employees: 42

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,728 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

3.44% less ownership

Funds ownership: 39.65% [Q1] → 36.21% (-3.44%) [Q2]

26% less funds holding

Funds holding: 38 [Q1] → 28 (-10) [Q2]

50% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 10

67% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 15

80% less capital invested

Capital invested by funds: $42.8M [Q1] → $8.66M (-$34.2M) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for VINC.

See Analyst Rankings

Financial journalist opinion

Vincerx Pharma Reports Second Quarter 2024 Financial Results

Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data expected at the end of Q3 2024

Vincerx Pharma Reports Second Quarter 2024 Financial Results

Zacks Investment Research

Vincerx Pharma (VINC) Moves to Buy: Rationale Behind the Upgrade

Vincerx Pharma (VINC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Vincerx Pharma (VINC) Moves to Buy: Rationale Behind the Upgrade

Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC)

Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants

PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an underwritten public offering of (i) 6,000,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 6,000,000 shares of common stock, and (ii) to certain investors, pre-funded warrants to purchase up to an aggregate of 16,000,000 shares of common stock and accompanying common stock warrants to purchase up to an aggregate of 16,000,000 shares of common stock. Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of $0.75, and each pre-funded warrant and accompanying common stock warrant are being sold together at a combined public offering price of $0.7499. Each pre-funded warrant will have an exercise price of $0.0001 per share and will be exercisable immediately after the original issue date until the pre-funded warrant is exercised in full. Each common stock warrant will have an exercise price of $1.00 per share, will be exercisable immediately after the original issue date and will expire 5 years from the date of issuance.

Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants

Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants

PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of common stock and accompanying common stock warrants to purchase shares of its common stock. All of the shares, pre-funded warrants and common stock warrants in the proposed offering will be offered by Vincerx. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants

Zacks Investment Research

Vincerx (VINC) Tumbles on Results From Cancer Therapy Study

Though early-stage results on Vincerx's (VINC) experimental drug did show signs of anti-tumor activity, the share price drops as some analysts stated that the results were below expectations.

Vincerx (VINC) Tumbles on Results From Cancer Therapy Study

Why Is Vincerx Pharma (VINC) Stock Down 64% Today?

Vincerx Pharma (NASDAQ: VINC ) stock is falling hard on Tuesday after releasing preliminary data from a Phase 1 clinical trial. Vincerx Pharma's cancer treatments did so potential in preliminary study results.

Why Is Vincerx Pharma (VINC) Stock Down 64% Today?

Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024

VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors

Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

VIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a virtual investor event on April 8 at 2:00 PM PT

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

Management to host virtual investor event on April 8 to highlight preliminary Phase 1 Data for VIP236, our first-in-class small molecule-drug conjugate (SMDC) Management to host virtual investor event on April 8 to highlight preliminary Phase 1 Data for VIP236, our first-in-class small molecule-drug conjugate (SMDC)

Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

See News Rankings

Charts implemented using Lightweight Charts™